Study On The Relationship Between The Expression Of ERCC1 And Platinum-Based Chemotherapy Resistance In Advanced Non-Small Cell Lung Cancer

Objective:The molecular predictor for cisplatin sensitivity in advanced non-small-cell lung cancer(NSCLC)is still an open question at present.The purpose of this study was to investigate the expression of the DNA damage repair enzymes Excision Repair Cross-Complementing 1(ERCC1)in the patients with advanced non-small-cell lung cancer(NSCLC)and determine the relationship between the expression of ERCC1 and cisplatin resistance.Methods:A total of 61 cases of stageⅢ,Ⅳnon-small-cell lung cancer(NSCLC) patients were included,All were pathologically confirmed.Bronchoscopa tumourbiopsies or lung puncture tumour biopsies assessed by streptavidin-peroxidase complex technique before chemotherapy.The expression of ERCC-1 were examined.All patients received cisplain contained regiment in tumor samples was examined by the immunohistochemical supervisiontm method.All patients received cisplatin contained regimen chemotherapy (Gemzar+DDP/CBP or NVB+DDP/CBP or TAT+DDP/CBP)4-6 cycles as the first line treatment.Chemotherapy tumor reponse rate(RR),1-year survival rate,desease control rate and time to progression(TTP)were assessed.The reponse rates and syrvival datas were analyzed according to the over-expression or not of the parameter.The relationship between the expression of ERCC1 and cisplatin resistance was analyzed by x~2 test.The syrvival data were analyzed by Kaplan-Meiner mothed.Results:Among those 61 cases,there were 23 cases expressing ERCC1.The positive rate was 37.7%.The expression level did not show any association with patient age,clinical stage and gender,but its expression rate in pulmonary adenocarcinoma was higher than those in squamous carcinoma.And its expression rate in smokers was higher than that in those who are not smoking.The expression of ERCC1 was associated with cisplatin resistance.In advanced non-small-cell lung cancer tissues.The RR,desease control rate and TTP were 26.1%,43.40%and 107.57±68.20 days in ERCC1 positive group respectively,and 63.1%, 81.5%and 260.78±98.56 days in ERCC1 negative group respectively.There were significant difference between the two groups(P=0.005,0.002 and 0.022 respectively).The 1-year survival rate was 35.5%in ERCC1 positive group respectively,and 60.27%in ERCC1 negative group respectively.There was also significant difference between the two groups. But there was no significant difference in the overal survical rate between the two groups(P=0.0735).Conclusion:In advanced non-small-cell lung cancer,There exsist the expression of ERCC1.It has no association with patient age,clinical stage and gender,but its expression rate in pulmonary adenocarcinoma was higher than that in squamous carcinoma.And its expression rate in smokers was higher than that in those who are not smoking.It is related to cispiatin resistance,.The difference expression of DNA damage repair enzymes Excision Repair Cross-Complementing 1(ERCC1)might be a molecule marker of chemotherapy sensitivity in NSCLC patients treated with cisplatin-based chemotherapy.The result of this syudy may provide a new sight for tailor chemotherapy to individual NSCLC patients.